Get the app
US › Healthcare

ADC Therapeutics SA (ADCT)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.06+0.95%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$19.2M
Revenue YoY
+2.2%
Net profit
$-16.6M
EPS
$-0.11
EPS estimate
$-0.19
Net margin
-86.1%

EPS came in at -0.11 against a street estimate of -0.19 — a beat of 42.1%.

Key statistics

Market cap
$136.6M
Forward P/E
0.0
P/B
3.42
Book value
$-1.79
EPS (TTM)
$-0.58
52-week high
$4.98
52-week low
$0.78
50-day MA
$1.17
200-day MA
$2.91
Beta
1.85

Analyst view

Analysts rate ADC Therapeutics SA a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $3.33.

Shareholding

Insiders
14.42%
Institutions
67.54%

Largest institutional holders

FundStake
Redmile Group, LLC9.03%
TCG Crossover Management, LLC8.92%
Prosight Management, LP6.13%
BlackRock Inc4.90%
Nantahala Capital Management, LLC4.38%
Morgan Stanley - Brokerage Accounts2.99%
Point72 Asset Management, L.P.2.65%
Millennium Management LLC2.27%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ADC Therapeutics SA — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.